[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Konstantinopoulos PA, Fountzilas E, Goldsmith JD, Bhasin M, Pillay K, Francoeur N, Libermann TA, Gebhardt MC, Spentzos D: Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance. PLoS One; 2010;5(4):e9747
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of multiple sarcoma expression datasets: implications for classification, oncogenic pathway activation and chemotherapy resistance.
  • BACKGROUND: Diagnosis of soft tissue sarcomas (STS) is challenging.
  • Many remain unclassified (not-otherwise-specified, NOS) or grouped in controversial categories such as malignant fibrous histiocytoma (MFH), with unclear therapeutic value.
  • We analyzed several independent microarray datasets, to identify a predictor, use it to classify unclassifiable sarcomas, and assess oncogenic pathway activation and chemotherapy response.
  • METHODOLOGY/PRINCIPAL FINDINGS: We analyzed 5 independent datasets (325 tumor arrays).
  • We developed and validated a predictor, which was used to reclassify MFH and NOS sarcomas.
  • Bayesian models of oncogenic pathway activation and chemotherapy response were applied to individual STS samples.
  • A 170-gene predictor was developed and independently validated (80-85% accuracy in all datasets).
  • Most MFH and NOS tumors were reclassified as leiomyosarcomas, liposarcomas and fibrosarcomas.
  • This classification revealed previously unrecognized tissue differentiation lines (adipocyte, fibroblastic, smooth-muscle) and was reproduced in paraffin specimens.
  • CONCLUSIONS/SIGNIFICANCE: STS profiling can aid in diagnosis through a predictor tracking distinct tissue differentiation in unclassified tumors, and in therapeutic management via oncogenic pathway activation and chemotherapy response assessment.
  • [MeSH-minor] Cluster Analysis. Databases, Nucleic Acid. Drug Resistance, Neoplasm / genetics. Expert Systems. Gene Expression Regulation, Neoplastic. Genome, Human. Humans. Soft Tissue Neoplasms / classification

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Breast Cancer Res. 2001;3(2):77-80 [11250749.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):626-32 [18235122.001]
  • [Cites] Curr Oncol Rep. 2001 May;3(3):243-9 [11296135.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3045-50 [11408500.001]
  • [Cites] Lancet. 2002 Apr 13;359(9314):1301-7 [11965276.001]
  • [Cites] N Engl J Med. 2002 Aug 15;347(7):472-80 [12181401.001]
  • [Cites] J Surg Oncol. 2008 Mar 15;97(4):330-9 [18286476.001]
  • [Cites] Methods Mol Biol. 2008;439:159-77 [18370102.001]
  • [Cites] JAMA. 2008 Apr 2;299(13):1574-87 [18387932.001]
  • [Cites] Expert Opin Ther Targets. 2008 May;12(5):589-603 [18410242.001]
  • [Cites] Clin Cancer Res. 2002 Oct;8(10):3034-8 [12374669.001]
  • [Cites] Nucleic Acids Res. 2003 Feb 15;31(4):e15 [12582260.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):543-8 [14962721.001]
  • [Cites] Neurochem Res. 2004 Jun;29(6):1213-22 [15176478.001]
  • [Cites] Cancer Treat Res. 2004;120:151-67 [15217223.001]
  • [Cites] Nature. 2004 Sep 16;431(7006):350-5 [15372042.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1799-807 [15509548.001]
  • [Cites] Ann Surg. 1987 Apr;205(4):349-59 [3566372.001]
  • [Cites] Am J Surg Pathol. 1992 Mar;16(3):213-28 [1317996.001]
  • [Cites] Verh Dtsch Ges Pathol. 1997;81:318-26 [9474886.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]
  • [Cites] Cell. 2005 Mar 11;120(5):635-47 [15766527.001]
  • [Cites] Cancer Res. 2005 Jul 1;65(13):5881-9 [15994966.001]
  • [Cites] Clin Cancer Res. 2005 Sep 1;11(17):6280-90 [16144932.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7332-41 [16145063.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9226-35 [16230383.001]
  • [Cites] Bioinformatics. 2005 Nov 15;21(22):4148-54 [16174683.001]
  • [Cites] Nature. 2006 Jan 19;439(7074):353-7 [16273092.001]
  • [Cites] N Engl J Med. 2006 Jun 8;354(23):2463-72 [16760446.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7390-4 [16885332.001]
  • [Cites] Nat Med. 2006 Nov;12(11):1294-300 [17057710.001]
  • [Cites] Biostatistics. 2007 Jan;8(1):118-27 [16632515.001]
  • [Cites] Orthop Nurs. 2007 Jan-Feb;26(1):4-11; quiz 12-3 [17273099.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):517-25 [17290060.001]
  • [Cites] Clin Transl Oncol. 2007 Mar;9(3):130-44 [17403624.001]
  • [Cites] Mod Pathol. 2007 Jul;20(7):749-59 [17464315.001]
  • [Cites] PLoS One. 2007;2(10):e1002 [17912341.001]
  • [Cites] PLoS One. 2007;2(11):e1195 [18030330.001]
  • [Cites] Cancer Res. 2008 Jan 15;68(2):346-51 [18199526.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):1-9 [18187804.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):48-56 [11262874.001]
  • (PMID = 20368975.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2848563
  •  go-up   go-down


2. Helfrich I, Scheffrahn I, Bartling S, Weis J, von Felbert V, Middleton M, Kato M, Ergün S, Augustin HG, Schadendorf D: Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med; 2010 Mar 15;207(3):491-503
Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma.
  • We hypothesized that the level of vessel maturation is critically involved in the response to antiangiogenic therapies.
  • To test this hypothesis, we evaluated the vascular network in spontaneously developing melanomas of MT/ret transgenic mice after using PTK787/ZK222584 for anti-VEGF therapy but also analyzed human melanoma metastases taken at clinical relapse in patients undergoing adjuvant treatment using bevacizumab.
  • Both experimental settings showed that tumor vessels, which are resistant to anti-VEGF therapy, are characterized by enhanced vessel diameter and normalization of the vascular bed by coverage of mature pericytes and immunoreactivity for desmin, NG-2, platelet-derived growth factor receptor beta, and the late-stage maturity marker alpha smooth muscle actin.
  • Our findings emphasize that the level of mural cell differentiation and stabilization of the vascular wall significantly contribute to the response toward antiangiogenic therapy in melanoma.
  • This study may be useful in paving the way toward a more rational development of second generation antiangiogenic combination therapies and in providing, for the first time, a murine model to study this.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Drug Resistance, Neoplasm. Melanoma / drug therapy. Melanoma / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2009 Feb 15;15(4):1384-92 [19228739.001]
  • [Cites] Blood. 2009 Apr 2;113(14):3139-46 [19171876.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2178-89 [10786682.001]
  • [Cites] Neuro Oncol. 2001 Apr;3(2):82-8 [11296484.001]
  • [Cites] J Biol Chem. 2001 Jul 13;276(28):26516-25 [11346644.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):341-5 [11809675.001]
  • [Cites] J Pathol. 2002 Mar;196(3):254-65 [11857487.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):985-1000 [11891196.001]
  • [Cites] Lab Invest. 2002 Apr;82(4):473-81 [11950904.001]
  • [Cites] J Pathol. 2002 Jul;197(3):355-62 [12115882.001]
  • [Cites] Clin Cancer Res. 2002 Aug;8(8):2714-24 [12171905.001]
  • [Cites] Endothelium. 2002;9(2):83-7 [12200959.001]
  • [Cites] J Clin Invest. 2003 May;111(9):1287-95 [12727920.001]
  • [Cites] J Clin Invest. 2003 Oct;112(8):1142-51 [14561699.001]
  • [Cites] Cell Tissue Res. 2003 Oct;314(1):15-23 [12883993.001]
  • [Cites] FASEB J. 2004 Feb;18(2):338-40 [14657001.001]
  • [Cites] J Biol Chem. 2004 Mar 26;279(13):12171-80 [14702352.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] Blood. 2004 Jun 1;103(11):4150-6 [14976056.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2335-42 [15175435.001]
  • [Cites] Nat Med. 2004 Oct;10(10):1133-8 [15361864.001]
  • [Cites] Nature. 1989 May 4;339(6219):58-61 [2469964.001]
  • [Cites] Muscle Nerve. 1989 Sep;12(9):723-34 [2630908.001]
  • [Cites] J Pathol. 1991 Jul;164(3):241-4 [1890549.001]
  • [Cites] Cell Tissue Res. 1992 Dec;270(3):469-74 [1283113.001]
  • [Cites] Muscle Nerve. 1995 Feb;18(2):175-84 [7823975.001]
  • [Cites] Cell. 1996 Aug 9;86(3):353-64 [8756718.001]
  • [Cites] Cell. 1996 Dec 27;87(7):1171-80 [8980224.001]
  • [Cites] Science. 1997 Jul 4;277(5322):55-60 [9204896.001]
  • [Cites] Science. 1997 Jul 4;277(5322):48-50 [9229772.001]
  • [Cites] Circ Res. 1997 Oct;81(4):567-74 [9314838.001]
  • [Cites] Am J Pathol. 1997 Nov;151(5):1417-23 [9358768.001]
  • [Cites] Development. 1998 May;125(9):1591-8 [9521897.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4625-9 [9539788.001]
  • [Cites] Pathol Oncol Res. 1998;4(1):62-75 [9555124.001]
  • [Cites] Oncogene. 1998 Oct 8;17(14):1885-8 [9778055.001]
  • [Cites] FASEB J. 1999 Jan;13(1):9-22 [9872925.001]
  • [Cites] Science. 1999 Jun 18;284(5422):1994-8 [10373119.001]
  • [Cites] Development. 1999 Jun;126(14):3047-55 [10375497.001]
  • [Cites] Melanoma Res. 1999 Jun;9(3):273-8 [10465583.001]
  • [Cites] EXS. 2005;(94):115-25 [15617474.001]
  • [Cites] Science. 2005 Jan 7;307(5706):58-62 [15637262.001]
  • [Cites] J Cell Sci. 2005 Feb 15;118(Pt 4):771-80 [15687104.001]
  • [Cites] Chembiochem. 2005 Mar;6(3):550-7 [15742376.001]
  • [Cites] Circ Res. 2005 Sep 16;97(6):512-23 [16166562.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):932-6 [16355210.001]
  • [Cites] Nature. 2005 Dec 15;438(7070):967-74 [16355214.001]
  • [Cites] Exp Cell Res. 2006 Mar 10;312(5):623-9 [16303125.001]
  • [Cites] Contrib Microbiol. 2006;13:118-37 [16627962.001]
  • [Cites] Eur Radiol. 2006 Jun;16(6):1191-205 [16528556.001]
  • [Cites] Trends Immunol. 2006 Dec;27(12):552-8 [17045842.001]
  • [Cites] N Engl J Med. 2007 Jan 11;356(2):125-34 [17215530.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):782-8 [17218488.001]
  • [Cites] Genes Dev. 2008 May 15;22(10):1276-312 [18483217.001]
  • [Cites] Cancer. 2009 Jan 1;115(1):119-27 [19090009.001]
  • [Cites] Ann Surg Oncol. 2009 Mar;16(3):751-60 [19116756.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1324-33 [19208839.001]
  • [ErratumIn] J Exp Med. 2013 Apr 8;210(4):853. Augustin, Helmut G [added]
  • (PMID = 20194633.001).
  • [ISSN] 1540-9538
  • [Journal-full-title] The Journal of experimental medicine
  • [ISO-abbreviation] J. Exp. Med.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / 8466
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Desmin; 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta
  • [Other-IDs] NLM/ PMC2839146
  •  go-up   go-down


3. Kyprianou N, Benning CM: Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis. Cancer Res; 2000 Aug 15;60(16):4550-5
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
  • Recent evidence from our laboratory has demonstrated that alpha1-adrenoceptor antagonists doxazosin and terazosin induced apoptosis in prostate epithelial and smooth muscle cells in patients with benign prostatic hypertrophy (BPH; J.
  • In this study, we investigated the biological action of three alpha1-adrenoceptor antagonists, doxazosin, terazosin, and tamsulosin, against prostate cancer cell growth.
  • The antigrowth effect of the three alpha1-adrenoceptor antagonists was examined in two human prostate cancer cell lines, PC-3 and DU-145, and a prostate smooth muscle cell primary culture, SMC-1, on the basis of: (a) cell viability assay;.
  • Our results indicate that treatment of prostate cancer cells with doxazosin or terazosin results in a significant loss of cell viability, via induction of apoptosis in a dose-dependent manner, whereas tamsulosin had no effect on prostate cell growth.
  • Neither doxazosin nor terazosin exerted a significant effect on the rate of cell proliferation in prostate cancer cells.
  • Exposure to phenoxybenzamine, an irreversible inhibitor of alpha1-adrenoceptors, does not abrogate the apoptotic effect of doxazosin or terazosin against human prostate cancer or smooth muscle cells.
  • Furthermore, an in vivo efficacy trial demonstrated that doxazosin administration (at tolerated pharmacologically relevant doses) in SCID mice bearing PC-3 prostate cancer xenografts resulted in a significant inhibition of tumor growth.
  • These findings demonstrate the ability of doxazosin and terazosin (but not tamsulosin) to suppress prostate cancer cell growth in vitro and in vivo by inducing apoptosis without affecting cell proliferation.
  • This evidence provides the rationale for targeting both drugs, already in clinical use and with established adverse-effect profiles, against prostatic tumors for the treatment of advanced prostate cancer.
  • [MeSH-major] Adrenergic alpha-1 Receptor Agonists. Adrenergic alpha-Antagonists / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Doxazosin / pharmacology. Prazosin / pharmacology. Prostatic Neoplasms / drug therapy
  • [MeSH-minor] Animals. Cell Division / drug effects. Cells, Cultured. Growth Inhibitors / pharmacology. Humans. Male. Mice. Mice, SCID. Muscle, Smooth / cytology. Muscle, Smooth / drug effects. Neoplasm Transplantation. Prostate / cytology. Prostate / drug effects. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Receptors, Adrenergic, alpha-1 / biosynthesis. Receptors, Adrenergic, alpha-1 / genetics. Reverse Transcriptase Polymerase Chain Reaction. Sulfonamides / pharmacology. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. Tamsulosin .
  • Hazardous Substances Data Bank. PRAZOSIN HYDROCHLORIDE .
  • Hazardous Substances Data Bank. DOXAZOSIN MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10969806.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Adrenergic alpha-1 Receptor Agonists; 0 / Adrenergic alpha-Antagonists; 0 / Antineoplastic Agents; 0 / Growth Inhibitors; 0 / RNA, Messenger; 0 / Receptors, Adrenergic, alpha-1; 0 / Sulfonamides; 8L5014XET7 / Terazosin; G3P28OML5I / tamsulosin; NW1291F1W8 / Doxazosin; XM03YJ541D / Prazosin
  •  go-up   go-down


Advertisement
4. Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A: High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol; 2008 Oct;10(5):700-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-grade glioma before and after treatment with radiation and Avastin: initial observations.
  • We evaluate the effects of adjuvant treatment with the angiogenesis inhibitor Avastin (bevacizumab) on pathological tissue specimens of high-grade glioma.
  • Tissue from five patients before and after treatment with Avastin was subjected to histological evaluation and compared to four control cases of glioma before and after similar treatment protocols not including bevacizumab.
  • Histological analysis focused on microvessel density and vascular morphology, and expression patterns of vascular endothelial growth factor-A (VEGF-A) and the hematopoietic stem cell, mesenchymal, and cell motility markers CD34, smooth muscle actin, D2-40, and fascin.
  • Vascular morphology showed apparent "normalization" after Avastin treatment in two cases, with thin-walled and evenly distributed vessels.
  • VEGF-A expression in tumor cells was increased in two cases and decreased in three and did not correlate with treatment response.
  • There was a trend toward a relative increase of CD34, smooth muscle actin, D2-40, and fascin immunostaining following treatment with Avastin.
  • Specimens from four patients with recurrent malignant gliomas before and after adjuvant treatment (not including bevacizumab) had features dissimilar from our study cases.
  • We conclude that a change in vascular morphology can be observed following antiangiogenic treatment.
  • While the phenomena we describe may not be specific to Avastin, they demonstrate the potential of tissue-based analysis for the discovery of clinically relevant treatment response biomarkers.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Antibodies, Monoclonal / therapeutic use. Brain Neoplasms / drug therapy. Brain Neoplasms / radiotherapy. Glioma / drug therapy. Glioma / radiotherapy
  • [MeSH-minor] Actins / drug effects. Actins / radiation effects. Adult. Antibodies, Monoclonal, Humanized. Antigens, CD34 / drug effects. Antigens, CD34 / radiation effects. Bevacizumab. Carrier Proteins / drug effects. Carrier Proteins / radiation effects. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Male. Microfilament Proteins / drug effects. Microfilament Proteins / radiation effects. Middle Aged. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy. Retrospective Studies. Vascular Endothelial Growth Factor A / drug effects. Vascular Endothelial Growth Factor A / radiation effects

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2001 Nov;7(11):1194-201 [11689883.001]
  • [Cites] Acta Neuropathol. 2003 Apr;105(4):358-64 [12624789.001]
  • [Cites] J Hematother Stem Cell Res. 2003 Feb;12(1):23-32 [12662433.001]
  • [Cites] Brain Pathol. 2003 Apr;13(2):133-43 [12744467.001]
  • [Cites] Oncogene. 2003 Jun 5;22(23):3616-23 [12789270.001]
  • [Cites] Brain Tumor Pathol. 2003;20(2):53-8 [14756441.001]
  • [Cites] Nat Rev Drug Discov. 2004 May;3(5):391-400 [15136787.001]
  • [Cites] Am J Pathol. 2004 Jul;165(1):35-52 [15215160.001]
  • [Cites] Endocr Rev. 2004 Aug;25(4):581-611 [15294883.001]
  • [Cites] Curr Opin Cell Biol. 2004 Oct;16(5):590-6 [15363811.001]
  • [Cites] Am J Clin Pathol. 1991 Jul;96(1):32-45 [1712542.001]
  • [Cites] J Neuropathol Exp Neurol. 1992 Sep;51(5):493-8 [1381414.001]
  • [Cites] J Neuropathol Exp Neurol. 1995 May;54(3):304-10 [7745429.001]
  • [Cites] Ann Oncol. 1996 Feb;7(2):205-7 [8777179.001]
  • [Cites] Acta Neuropathol. 1999 May;97(5):481-90 [10334485.001]
  • [Cites] Microsc Res Tech. 1999 Jul 1;46(1):53-8 [10402272.001]
  • [Cites] APMIS. 2004 Jul-Aug;112(7-8):450-62 [15563309.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 29;333(2):328-35 [15961063.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Nov 11;337(1):355-62 [16185662.001]
  • [Cites] Oncology. 2005;69 Suppl 3:11-6 [16301831.001]
  • [Cites] Ann Diagn Pathol. 2005 Dec;9(6):307-11 [16308158.001]
  • [Cites] Brain Pathol. 2005 Oct;15(4):297-310 [16389942.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):217-27 [16365183.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):769-77 [16391297.001]
  • [Cites] Virchows Arch. 2006 Apr;448(4):493-9 [16411134.001]
  • [Cites] Cancer Cell. 2006 Apr;9(4):261-72 [16616332.001]
  • [Cites] Acta Neuropathol. 2006 May;111(5):483-8 [16596424.001]
  • [Cites] J Cell Biol. 2006 Sep 11;174(6):863-75 [16966425.001]
  • [Cites] Histol Histopathol. 2006 Dec;21(12):1287-93 [16977579.001]
  • [Cites] J Clin Invest. 2006 Oct;116(10):2610-21 [17016557.001]
  • [Cites] J Cell Sci. 2006 Nov 1;119(Pt 21):4541-53 [17046996.001]
  • [Cites] J Pediatr Hematol Oncol. 2006 Nov;28(11):703-10 [17114955.001]
  • [Cites] Arch Pathol Lab Med. 2007 Feb;131(2):234-41 [17284108.001]
  • [Cites] Am J Surg Pathol. 2007 Mar;31(3):351-62 [17325476.001]
  • [Cites] Mod Pathol. 2007 May;20(5):552-61 [17396145.001]
  • [Cites] Dis Markers. 2007;23(3):153-60 [17473384.001]
  • [Cites] Leukemia. 2007 Jun;21(6):1310-2 [17330095.001]
  • [Cites] Nat Rev Neurosci. 2007 Aug;8(8):610-22 [17643088.001]
  • [Cites] Circ Res. 2007 Aug 3;101(3):286-94 [17569886.001]
  • [CommentIn] Neuro Oncol. 2008 Oct;10(5):647 [18776128.001]
  • (PMID = 18697955.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Angiogenesis Inhibitors; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD34; 0 / Carrier Proteins; 0 / Microfilament Proteins; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 146808-54-0 / fascin; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ PMC2666246
  •  go-up   go-down


5. Morawietz L, Kuhnen C, Katenkamp D, Le Coutre P, Ladhoff A, Petersen I: Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma. Virchows Arch; 2005 Dec;447(6):990-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual sarcomatoid neoplasm of the lung suggesting a myofibrosarcoma.
  • Myofibrosarcoma is a rare neoplasm that occurs mainly in the head and neck region and extremities of middle-aged patients.
  • We report the case of a 47-year-old male patient with a malignant mesenchymal pulmonary tumor affecting almost the entire lower left lobe.
  • Clinically suggestive for a lung carcinoma, the tumor showed typical features of a myofibrosarcoma.
  • A major spindle cell component was observed being positive for smooth-muscle actin, calponin, and vimentin, while stainings for desmin, h-caldesmon, alkaline phosphatase (ALK), and extensively studied cytokeratins were negative.
  • Shortly after resection of the primary tumor, the patient showed multiple distant metastases in the contralateral lung, the mediastinal lymph nodes, the left adrenal gland, and the pectoral and deltoid muscle, which responded well to chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1973 Jan;31(1):191-208 [4683037.001]
  • [Cites] Hum Pathol. 1996 Oct;27(10):1095-8 [8892598.001]
  • [Cites] Pathologe. 2003 Mar;24(2):128-35 [12673503.001]
  • [Cites] Am J Surg Pathol. 2001 Feb;25(2):219-28 [11176071.001]
  • [Cites] J Dermatol. 2001 Jul;28(7):383-7 [11510507.001]
  • [Cites] Am J Clin Pathol. 1994 Sep;102(3):331-40 [8085557.001]
  • [Cites] Am J Surg Pathol. 2001 Dec;25(12 ):1501-7 [11717539.001]
  • [Cites] Ultrastruct Pathol. 1993 Nov-Dec;17(6):611-22 [8122327.001]
  • [Cites] Cancer Genet Cytogenet. 2002 Aug;137(1):33-42 [12377411.001]
  • [Cites] Am J Surg Pathol. 1998 Feb;22(2):141-7 [9500214.001]
  • [Cites] Verh Dtsch Ges Pathol. 1998;82:75-82 [10095420.001]
  • [Cites] Cancer. 2002 Jan 15;94(2):459-69 [11905413.001]
  • [Cites] Am J Surg Pathol. 1998 Oct;22(10):1228-38 [9777985.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Am J Surg Pathol. 2002 Mar;26(3):393-4; author reply 394-6 [11981942.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):350-62 [8996162.001]
  • [Cites] Br J Cancer. 1997;75(1):79-86 [9000602.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):41-54 [14968417.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13784-9 [11707590.001]
  • [Cites] Am J Surg Pathol. 1997 Apr;21(4):489-96 [9130998.001]
  • [Cites] Am J Surg Pathol. 1979 Dec;3(6):535-42 [534390.001]
  • [Cites] Virchows Arch. 2004 Sep;445(3):215-23 [15173943.001]
  • (PMID = 16158184.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


6. Meşină C, Vasile I, Vîlcea ID, Vere CC, Georgescu CV, Ghiluşi M, Paşalega M, Pârvănescu H, Calotă F, Mogoantă SS: Axillary and perianal leiomyosarcoma: report of two cases. Rom J Morphol Embryol; 2010;51(2):379-85
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Soft tissue leiomyosarcoma is a relatively rare malignant tumor.
  • To make a correct identification of soft tissue leiomyosarcoma, immunostaining with several smooth muscle differentiation markers (actin, calponin and desmin), and negative staining results with S100 (to rule out Schwann cell neoplasm), c-kit and CD34 (to rule out gastrointestinal stromal tumors) is needed.
  • Prompt diagnosis and referral are desirable, since the size of the tumor at presentation is a continuous variable for the risk of local recurrence and metastatic disease.
  • Chemosensitivity varies according to the tumor subtype, and the tumor grade, the patient's age, performance status, and the timing of metastatic disease further influence the likelihood of a response and survival.
  • Chemotherapy is palliative for most patients with unresectable or metastatic disease.
  • Ifosfamide and doxorubicin are routinely used in this setting; doxorubicin as a single agent is considered the drug of choice.
  • [MeSH-minor] Aged. Axilla / pathology. Doxorubicin / therapeutic use. Female. Humans. Male

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Anal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20495760.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 80168379AG / Doxorubicin
  •  go-up   go-down


7. Punt SE, Eary JF, O'Sullivan J, Conrad EU: Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics. Nucl Med Commun; 2009 Jul;30(7):546-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fluorodeoxyglucose positron emission tomography in leiomyosarcoma: imaging characteristics.
  • OBJECTIVE: Leiomyosarcoma, a malignant neoplasm of smooth muscle, accounts for 7% of the sarcomas.
  • These tumors, which are derived from mesenchymal tissues, are difficult to diagnose, and treatment options remain controversial.
  • The relatively rare incidence of this soft tissue sarcoma subtype has limited the number of patients available for studies and research.
  • This study examines whether the imaging characteristics of positron emission tomography (PET) with radiolabeled fluorodeoxyglucose (FDG) provide a reliable, noninvasive means to predict tumor behavior in patients with leiomyosarcomas.
  • METHODS: [18F]-FDG-PET was performed on the tumors of participating patients before the neoadjuvant chemotherapy or resection, and a maximum tumor standard uptake value (SUVmax) was calculated.
  • RESULTS: The SUVmax was correlated with tumor grade (P=0.001) and tumor size as greatest dimension (P=0.004).
  • Analysis of these data indicated the potential effectiveness of FDG-PET imaging in predicting tumor grade.
  • CONCLUSION: In leiomyosarcoma, the SUVmax from FDG-PET is a likely predictor of tumor behavior.
  • The results of this study suggest that a large (by greatest dimension) intermediate grade tumor is expected to have the same predicted outcome as a high-grade tumor and should be treated in the same manner, as they share the same prognosis by definition of tumor grade.
  • Improvements made in the clinical treatment of leiomyosarcomas by use of FDG-PET imaging data may lead to an increase in patient survival.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 2004;86-A Suppl 2:98-104 [15691114.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8828-34 [16314643.001]
  • [Cites] Clin Cancer Res. 1998 May;4(5):1215-20 [9607579.001]
  • [Cites] Ann Surg. 2000 Apr;231(4):500-5 [10749609.001]
  • [Cites] Clin Cancer Res. 2000 Apr;6(4):1279-87 [10778952.001]
  • [Cites] Ann Surg. 2001 Oct;234(4):540-7; discussion 547-8 [11573047.001]
  • [Cites] Skeletal Radiol. 2001 Oct;30(10):543-59 [11685477.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Sep;29(9):1149-54 [12192559.001]
  • [Cites] J Nucl Med. 2003 Jun;44(6):930-42 [12791822.001]
  • [Cites] Gynecol Oncol. 2004 Feb;92(2):701-4 [14766270.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Feb;31(2):189-95 [15129700.001]
  • [Cites] Ir J Med Sci. 2011 Dec;180(4):889-91 [19184604.001]
  • [Cites] Clin Orthop Relat Res. 2009 Jun;467(6):1605-11 [19048352.001]
  • [Cites] Wien Klin Wochenschr. 2007;119(17-18):557-60 [17943409.001]
  • [Cites] Ann Thorac Surg. 2007 May;83(5):1826-9; discussion 1829-30 [17462407.001]
  • [Cites] Kyobu Geka. 2006 Dec;59(13):1191-6 [17163213.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Nov;33(11):1290-5 [16832631.001]
  • (PMID = 19440162.001).
  • [ISSN] 1473-5628
  • [Journal-full-title] Nuclear medicine communications
  • [ISO-abbreviation] Nucl Med Commun
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA065537-13; United States / NCI NIH HHS / CA / R01 CA065537; United States / NCI NIH HHS / CA / R01 CA 65537; United States / NCI NIH HHS / CA / R01 CA065537-13
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Other-IDs] NLM/ NIHMS121746; NLM/ PMC2752415
  •  go-up   go-down


8. Soares AB, Lins LH, Macedo AP, Pereira-Neto JS, Vargas PA: Fibrosarcoma originating in the mandible. Med Oral Patol Oral Cir Bucal; 2006 May;11(3):E243-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fibrosarcoma is a malignant mesenchymal neoplasm of fibroblasts that rarely affects the oral cavity and can cause local recurrences or metastasis.
  • Microscopically the tumor showed an intense proliferation of spindle-shaped cells, varying little in size and shape and arranged in parallel bands, partly crossing each other, the mitotic activity was increased and there was nuclear pleomorphism.
  • Immunohistochemically the cells only showed immunoreactivity for vimentin and negativity for S-100 protein, CD 68, cytokeratin cocktail, HMB-45, CD34, pan actin HHF 35, desmin, smooth muscle actin and epithelial membrane antigen (EMA).
  • The treatment choice was radical surgery with mandibular reconstruction.
  • After one year and nine months of the treatment the patient displayed multiple metastases.
  • Radiation therapy and chemotherapy were used as adjuvant treatment.

  • Genetic Alliance. consumer health - Fibrosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648761.001).
  • [ISSN] 1698-6946
  • [Journal-full-title] Medicina oral, patología oral y cirugía bucal
  • [ISO-abbreviation] Med Oral Patol Oral Cir Bucal
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


9. Bodner K, Bodner-Adler B, Czerwenka K, Hudelist G, Kimberger O, Leodolter S, Mayerhofer K: Bcl-2 expression in a primary leiomyosarcoma of the ovary: a case report. Wien Klin Wochenschr; 2003 Mar 31;115(5-6):191-5
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth-muscle neoplasm with fewer than 30 documented cases worldwide.
  • Immunohistochemically, ovarian leiomyosarcomas are characterized by the expression of alpha-smooth muscle actin (alpha-SMA).
  • Surgical exploration revealed a large left adnexal mass that had developed from the left ovary and infiltrated one part of the omentum adherent to the left adnexa.
  • Microscopically the left adnexal tumor consisted of spindle cells arranged in smooth-muscle bundles and fascicles.
  • The tumor was characterized by high cellularity and nuclear polymorphism, as well as patchy necrosis and large areas of hemorrhage.
  • The tumor appeared encapsulated, and the capsule was partially disrupted by tumor cells.
  • Immunohistochemically, the tumor showed a strong staining reaction for muscle actin, alpha-SMA and neuron-specific enolase, and also a weak reaction for vimentin.
  • According to the FIGO staging system for ovarian cancer, the tumor was classified as a primary ovarian leiomyosarcoma stage III C, and the patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • Two days after the third cycle of cisplatin/ifosfamid she developed an apoplexy spontaneously and chemotherapy was therefore discontinued.
  • In order to understand more about the nature and the behaviour of this highly malignant neoplasm and to be able to improve the treatment, the prognostic value of bcl-2 has to be investigated in additional studies.
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Ovariectomy. Ovary / pathology

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Postgrad Med. 1993 Jul-Sep;39(3):151-3 [8051647.001]
  • [Cites] Gynecol Oncol. 1987 Sep;28(1):116-20 [3308653.001]
  • [Cites] Br J Cancer. 1995 May;71(5):1003-7 [7734290.001]
  • [Cites] Exp Cell Res. 1991 Aug;195(2):277-83 [2070813.001]
  • [Cites] Gynecol Oncol. 1993 Mar;48(3):389-93 [8462904.001]
  • [Cites] Am J Pathol. 1996 Dec;149(6):1941-52 [8952529.001]
  • [Cites] N Engl J Med. 1993 Sep 2;329(10):690-4 [8393963.001]
  • [Cites] Arch Pathol Lab Med. 1991 Sep;115(9):941-5 [1929791.001]
  • [Cites] J Cell Biol. 1994 Jan;124(1-2):1-6 [8294493.001]
  • [Cites] Br J Cancer. 1999 Jul;80(10):1658-64 [10408415.001]
  • [Cites] Cell. 1991 Jun 28;65(7):1097-8 [1648446.001]
  • [Cites] Eur J Gynaecol Oncol. 1999;20(3):172-3 [10410877.001]
  • [Cites] Pathol Int. 2000 Feb;50(2):162-5 [10792777.001]
  • [Cites] J Obstet Gynaecol Res. 2000 Dec;26(6):401-7 [11152324.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):499-504 [8133533.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jan;82(1):293-9 [8989276.001]
  • [Cites] Proc Natl Acad Sci U S A. 1986 Jul;83(14):5214-8 [3523487.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):745-8 [12445253.001]
  • [Cites] Eur J Gynaecol Oncol. 1998;19(3):257-61 [9641226.001]
  • [Cites] Gynecol Oncol. 1997 Sep;66(3):519-25 [9299270.001]
  • [Cites] Gynecol Oncol. 1987 Feb;26(2):183-92 [3643159.001]
  • [Cites] Am J Obstet Gynecol. 1972 Jan 15;112(2):183-91 [4109398.001]
  • (PMID = 12741081.001).
  • [ISSN] 0043-5325
  • [Journal-full-title] Wiener klinische Wochenschrift
  • [ISO-abbreviation] Wien. Klin. Wochenschr.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Austria
  • [Chemical-registry-number] 0 / Proto-Oncogene Proteins c-bcl-2
  •  go-up   go-down


10. Craver RD, Lipscomb JT, Suskind D, Velez MC: Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components. Ann Diagn Pathol; 2001 Oct;5(5):285-92
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant teratoma of the thyroid with primitive neuroepithelial and mesenchymal sarcomatous components.
  • A 15-year-old black girl had a near total resection of a malignant thyroid teratoma with bilateral nodal involvement and mediastinal extension.
  • A malignant spindle cell component stained for smooth-muscle actin, muscle actin, and to a lesser extent S-100.
  • Loose myxoid tissue resembled primitive cartilage.
  • The tumor from the left and right thyroid lobes exhibited trisomy 8, the right also had hyperdiploid cell lines.
  • She was treated with aggressive combination chemotherapy and radiation.
  • Malignant thyroid teratoma is an aggressive tumor, with 15 of 27 reported patients dying 2 weeks to 3 years after diagnosis.
  • Survivors have been treated with total or subtotal resection, combination chemotherapy with agents effective in the treatment of germ cell tumors as well as sarcomas, and radiation for either recurrent or residual disease.
  • The heterologous elements, lacking MIC2 staining and t(11;22), support the diagnosis of malignant teratoma rather than a neuroepithelial tumor.
  • Trisomy 8 is the first cytogenetic abnormality described in malignant thyroid teratoma.
  • Therapy should be tailored to the management of all transformed histologies.
  • [MeSH-minor] Adolescent. Aneuploidy. Antineoplastic Combined Chemotherapy Protocols. Biomarkers, Tumor / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. DNA, Neoplasm / analysis. Diagnosis, Differential. Female. Humans. Image Cytometry. Prognosis. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Teratoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 by W.B. Saunders Company
  • (PMID = 11598856.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Number-of-references] 34
  •  go-up   go-down


11. Lifschitz O, Ziv-Sokolovsky N, Ben-Aharon U: [Acute rectal bleeding from malignant stromal tumor]. Harefuah; 2002 Dec;141(12):1019-20, 1092
MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Acute rectal bleeding from malignant stromal tumor].
  • A case report of a 61 years old female admitted with acute bleeding due to malignant stromal tumor of the rectum is described.
  • Preoperative assessments revealed a large tumor located in the rectal wall with extension to the adjacent tissues.
  • The histologic features of needle biopsy was compatible with gastrointestinal stromal tumor.
  • The definitive histological examination showed a gastrointestinal stromal tumor (GISTs), spindle cell type with mucosal invasion, vast necrosis and highly mitotic activity.
  • The tumor cells coexpressed CD34 and smooth muscle actin and were negative for staining desmin and S-100 protein.
  • Adjuvant chemotherapy was given.
  • We decided to describe a rare malignant stromal tumor of the rectum with uncommon clinical presentation.
  • [MeSH-minor] Antigens, CD34 / analysis. Biopsy, Needle. Chemotherapy, Adjuvant. Fatal Outcome. Female. Humans. Middle Aged. Neoplasm Invasiveness. Stromal Cells / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12534196.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Israel
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


12. Yamate J, Kotera T, Kuwamura M, Kotani T: Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines. Exp Toxicol Pathol; 2007 Apr;58(5):299-309
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Potential osteogenic differentiation of cisplatin-resistant rat malignant fibrous histiocytoma-derived cell lines.
  • Histological modulations in tumor cells treated with anti-cancer drugs have been reported.
  • The histogenesis of malignant fibrous histiocytoma (MFH) remains elusive.
  • Immunohistochemically, MT-10 reacted to vimentin, alpha-smooth muscle actin (a marker of myofibroblasts), ED1/ED2 (rat macrophage/histiocyte-specific antibodies), and A3 (rat MFH-specific antibody) in varying degrees, indicating that MFH cells have features of both fibroblasts and histiocytes.
  • MT-10 developed tumors of a storiform pattern, while MT-10R and MT-PR tumors comprise round or polygonal cells arranged in a compact sheet.
  • Cisplatin-resistant MFH cells had potential to differentiate into osteogenic tissues by producing osteogenic factors, suggesting that MFH histology may be altered under anti-cancer drug treatments.
  • Recently, cancer differentiation-based therapy, that could be induced by anti-cancer drugs, has been implied.
  • MT-10R and MT-PR become useful experimental systems for studies on cellular differentiation provoked by anti-cancer drugs.
  • [MeSH-major] Bone Morphogenetic Proteins / biosynthesis. Cell Differentiation / drug effects. Cisplatin / pharmacology. Drug Resistance, Neoplasm / drug effects. Histiocytoma, Malignant Fibrous / pathology. Osteoblasts / pathology
  • [MeSH-minor] Animals. Bone Morphogenetic Protein 1. Bone Morphogenetic Protein 6. Clone Cells. Enzyme-Linked Immunosorbent Assay. Immunohistochemistry. Metalloendopeptidases / biosynthesis. Neoplasm Transplantation. Osteopontin / biosynthesis. RNA, Messenger / biosynthesis. Rats. Rats, Inbred F344. Reverse Transcriptase Polymerase Chain Reaction. Tumor Cells, Cultured

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17267196.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Bmp6 protein, rat; 0 / Bone Morphogenetic Protein 6; 0 / Bone Morphogenetic Proteins; 0 / RNA, Messenger; 106441-73-0 / Osteopontin; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.19 / Bmp1 protein, rat; EC 3.4.24.19 / Bone Morphogenetic Protein 1; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


13. Pirraco A, Coelho P, Rocha A, Costa R, Vasques L, Soares R: Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells. J Cell Biochem; 2010 Oct 1;111(2):433-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib targets PDGF signaling in melanoma and host smooth muscle neighboring cells.
  • In previous in vitro studies, we showed that imatinib abrogated platelet-derived growth factor receptor α (PDGFRα) signaling, disrupting both breast cancer and smooth muscle cells (SMC).
  • In a mouse model of B16 melanoma, intraperitoneal administration of imatinib at early day light significantly decreased tumor growth.
  • Altogether, this study demonstrates that besides targeting tumor cells, imatinib also prevents vascular integrity.
  • The current study provides evidence that the paracrine crosstalk between tumor cells and host neighboring cells is crucial for the elucidation of imatinib effects.
  • In addition, the fact that this molecule targets vascular support cells further enlarges its therapeutic purpose to a wide range of vasculoproliferative pathologies.
  • [MeSH-major] Melanoma, Experimental / drug therapy. Myocytes, Smooth Muscle / drug effects. Piperazines / pharmacology. Platelet-Derived Growth Factor / drug effects. Pyrimidines / pharmacology. Signal Transduction / drug effects
  • [MeSH-minor] Animals. Benzamides. Imatinib Mesylate. Mice. Muscle, Smooth, Vascular / pathology. Neovascularization, Pathologic. Paracrine Communication

  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Wiley-Liss, Inc.
  • (PMID = 20518073.001).
  • [ISSN] 1097-4644
  • [Journal-full-title] Journal of cellular biochemistry
  • [ISO-abbreviation] J. Cell. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzamides; 0 / Piperazines; 0 / Platelet-Derived Growth Factor; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate
  •  go-up   go-down


14. Kinkor Z, Hes O: [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature]. Cesk Patol; 2007 Jul;43(3):103-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Pleomorphic epithelioid/clear cell malignant tumor of the uterus exhibiting both myoid and melanocytic differentiation--leiomyosarcoma or PEComa? A case report and a review of the literature].
  • [Transliterated title] Pleomorfni epiteloidni a svetlobunecný maligní tumor delohy s myoidní a melanocytární diferenciací--leiomyosarkom nebo PECom? Kazuistika a prehled literatury.
  • The neoplasm broadly invaded myometrium with no evidence of endometrial cavity involvement.
  • Microscopically, the tumor displayed solid mosaic pattern and consisted of large epithelioid cells with ample eosinophilic, finely granular cytoplasm ongoing apparent clear cell change elsewhere.
  • Unusual complex phenotype included co-expression of vimentin, smooth muscle actin, desmin, HMB45, Melan A, CD10 and EMA.
  • No obvious stigmata of tuberous sclerosis were found and a five months follow-up after chemotherapy indicated no progression of disease.
  • With some uncertainty the tumor was finally rendered as pleomorphic leiomyosarcoma with peculiar melanocytic differentiation.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17821838.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


15. Mayerhofer K, Lozanov P, Bodner K, Bodner-Adler B, Mayerhofer-Gallenbacher N, Hudelist G, Czerwenka K: Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report. Anticancer Res; 2003 Jul-Aug;23(4):3433-6
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Primary ovarian leiomyosarcoma is an extremely rare malignant smooth muscle neoplasm.
  • CASE REPORT: Surgical exploration in a 71-year-old woman revealed a large left adnexal tumor and one separate metastatic implant in one part of the omentum, being classified as a primary ovarian leiomyosarcoma stage III C.
  • The patient was treated with an adjuvant chemotherapy regimen consisting of cisplatin and ifosfamide.
  • High cellularity, nuclear polymorphism as well as patchy necrosis and large areas of hemorrhage, characterized the tumor.
  • Immunohistochemically, the tumor showed a strong positive staining reaction for muscle actin, alpha-smooth muscle actin and neuron-specific enolase as well as a weak positive reaction for vimentin.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12926085.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Endothelial Growth Factors; 0 / Intercellular Signaling Peptides and Proteins; 0 / Ki-67 Antigen; 0 / Lymphokines; 0 / Receptors, Estrogen; 0 / Receptors, Progesterone; 0 / Vascular Endothelial Growth Factor A; 0 / Vascular Endothelial Growth Factors; EC 3.4.24.24 / Matrix Metalloproteinase 2; EC 3.4.24.7 / Matrix Metalloproteinase 1
  •  go-up   go-down


16. Pezzolo A, Parodi F, Corrias MV, Cinti R, Gambini C, Pistoia V: Tumor origin of endothelial cells in human neuroblastoma. J Clin Oncol; 2007 Feb 1;25(4):376-83
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor origin of endothelial cells in human neuroblastoma.
  • PURPOSE: Malignant cells are genetically unstable and prone to develop chemotherapy resistance, whereas tumor vasculature is usually of host origin and genetically stable.
  • Tumor endothelial microvessels attract interest as therapeutic targets, but their genetic instability would curtail such approach.
  • Here, we have investigated the tumor origin of endothelial microvessels in human neuroblastoma (NB).
  • MATERIALS AND METHODS: Paraffin-embedded tissue sections from 10 MYCN-amplified tumors (six stage 4, three stage 3, and one stage 1) were studied.
  • RESULTS: MYCN-amplified ECs formed approximately 70% of tumor endothelial microvessels in two stage 4 tumors and 20% in one stage 3 tumor.
  • Staining for alpha-smooth muscle actin in combination with MYCN FISH demonstrated that tumor-derived ECs were coated with pericytes.
  • Approximately 70% of endothelial vessels from HTLA-230 xenografts stained for human CD31, but not murine CD34, and displayed MYCN amplification, thus proving their tumor origin.
  • CONCLUSION: NB-associated endothelial microvessels can originate from tumor cells, and this finding challenges the tenet that tumor vasculature is genetically stable.
  • The possibility that NB-derived ECs are chemotherapy resistant warrants further investigation.
  • [MeSH-minor] Animals. Antigens, CD / genetics. Antigens, CD / metabolism. Antigens, CD31 / genetics. Antigens, CD31 / metabolism. Drug Resistance, Neoplasm. Gene Amplification. Humans. In Situ Hybridization, Fluorescence. Mice. Mice, SCID. Microcirculation. Nuclear Proteins / genetics. Nuclear Proteins / metabolism. Oncogene Proteins / genetics. Oncogene Proteins / metabolism. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17264333.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD31; 0 / ENG protein, human; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / Receptors, Cell Surface
  •  go-up   go-down


17. Rocha LA, Rizo VH, Romañach MJ, de Almeida OP, Vargas PA: Oral metastasis of alveolar soft-part sarcoma: a case report and review of literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2010 Apr;109(4):587-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alveolar soft-part sarcoma (ASPS) is a rare malignant neoplasm with uncertain histogenesis and with a distinctive morphology.
  • A 27-year-old male patient, who was under chemotherapy treatment for ASPS of the thigh, presented in our dental clinic with a painless and pedunculated nodule on the right tuber maxillae.
  • The nodule was erythematous with smooth and lobular surface, measuring 3 cm in maximum diameter.
  • Histologically, the tumor was characterized by a proliferation of polyhedral cells in pseudoalveolar pattern.
  • Tumor cells were large, showing granular cytoplasm, periodic acid-Schiff positive diastase-resistant intracytoplasmic material, and vesicular nuclei with prominent nucleoli.
  • [MeSH-minor] Adult. Brain Neoplasms / secondary. Cell Nucleolus / ultrastructure. Cell Nucleus / ultrastructure. Cytoplasm / ultrastructure. Diagnosis, Differential. Fatal Outcome. Gingival Diseases / diagnosis. Granuloma, Giant Cell / diagnosis. Granuloma, Pyogenic / diagnosis. Humans. Male. Muscle Neoplasms / pathology. Thigh / pathology

  • Genetic Alliance. consumer health - Alveolar Soft Part Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Mosby, Inc. All rights reserved.
  • (PMID = 20303057.001).
  • [ISSN] 1528-395X
  • [Journal-full-title] Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics
  • [ISO-abbreviation] Oral Surg Oral Med Oral Pathol Oral Radiol Endod
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Macák J, Mukensnábl P, Kawano N, Bobot L, Dusková M, Vácha P: [Intra-abdominal desmoplastic small-cell tumor of the peritoneum]. Cesk Patol; 2003 Apr;39(2):69-75

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intra-abdominal desmoplastic small-cell tumor of the peritoneum].
  • Intensive chemotherapy was applied but two patients died of generalisation.
  • The "classical" type of IDSRT was found in all the cases.
  • In 2 cases the reaction to desmin was seen in a dot-like paranuclear distribution, whereas the reaction to smooth muscle actin (MSA) was negative.
  • Many different tumour types, such as lymphoma, Ewing sarcoma/PNET, neuroblastoma, alveolar rhabdomyosarcoma, malignant mesothelioma must be excluded.
  • [MeSH-minor] Abdomen / pathology. Adult. Female. Humans. Immunohistochemistry. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12874904.001).
  • [ISSN] 1210-7875
  • [Journal-full-title] Československá patologie
  • [ISO-abbreviation] Cesk Patol
  • [Language] cze
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


19. Jeanrot C, Ouaknine M, Anract P, Carlioz A, Forest M, Tomeno B: [Primary leiomyosarcoma of bone. Report of 5 anatomo-clinical cases and review of the literature]. Rev Chir Orthop Reparatrice Appar Mot; 2000 Feb;86(1):63-73
MedlinePlus Health Information. consumer health - Bone Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Leiomyosarcoma is a malignant smooth muscle tumor occurring most frequently in uterus or soft tissues and more rarely in bone.
  • RESULTS: The tumors were located respectively in the distal tibia (n=2), the distal femur, the sternum and the ilium (n=1).
  • This tumor arises more commonly in adults (mean age: 49 years) with an equal gender distribution and involves predominantly the long bones near the knee.
  • The diagnosis is based on microscopic features demonstrating fusiform tumor cells arranged in interwoven bundles, and the immunohistochemical results of widespread cytoplasmic positivity for smooth muscle actin.
  • Surgery constitutes the main treatment since chemotherapy or radiotherapy did not provide an improved prognosis over a wide resection.

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10669826.001).
  • [ISSN] 0035-1040
  • [Journal-full-title] Revue de chirurgie orthopédique et réparatrice de l'appareil moteur
  • [ISO-abbreviation] Rev Chir Orthop Reparatrice Appar Mot
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 53
  •  go-up   go-down


20. Yang JY, Kim JM: Small cell extraskeletal osteosarcoma. Orthopedics; 2009 Mar;32(3):217
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Extraskeletal osteosarcoma is a rare malignant mesenchymal neoplasm that accounts for <4% of all osteosarcomas and approximately 1.2% of all soft tissue sarcomas.
  • Among the extraskeletal osteosarcomas, the small cell type is extremely rare.
  • This article describes a 31-year-old man who had small cell extraskeletal osteosarcoma arising from the semimembranosus muscle.
  • The results were reported as a malignant small round cell tumor, consistent with an extraskeletal Ewing's sarcoma or primitive neuroectodermal tumor.
  • Immunohistochemically, the tumor showed reactivity with antibodies against CD99 and neuron-specific enolase, but not with antibodies against S100 protein, CD138, alpha smooth muscle actin, chromogranin, Ki-67, leukocyte common antigen, epithelial membrane antigen, CD30, or desmin.
  • The patient refused neoadjuvant chemotherapy.
  • Adjuvant chemotherapy was performed using doxorubicin, ifosfamide, and cisplatin together with a total of 60 Gy of radiation therapy.
  • We performed chest computed tomography, magnetic resonance imaging, and positron emission tomography-computed tomography.
  • [MeSH-major] Muscle Neoplasms / pathology. Osteosarcoma / pathology. Sarcoma, Small Cell / pathology
  • [MeSH-minor] Adult. Antigens, CD / analysis. Biomarkers, Tumor / analysis. Cell Adhesion Molecules / analysis. Combined Modality Therapy. Disease-Free Survival. Humans. Male. Muscle, Skeletal / pathology

  • Genetic Alliance. consumer health - Osteosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19309043.001).
  • [ISSN] 1938-2367
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules
  •  go-up   go-down


21. Gebhard S, Coindre JM, Michels JJ, Terrier P, Bertrand G, Trassard M, Taylor S, Château MC, Marquès B, Picot V, Guillou L: Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group. Am J Surg Pathol; 2002 May;26(5):601-16
Genetic Alliance. consumer health - Liposarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleomorphic liposarcoma: clinicopathologic, immunohistochemical, and follow-up analysis of 63 cases: a study from the French Federation of Cancer Centers Sarcoma Group.
  • Tumor size ranged from 2 to 23 cm (median 10 cm).
  • Tumor locations included lower extremity (36.5%), especially the thigh (28.5%), limb girdles (17.5%), upper extremity (16%), thoracoabdominal wall (9.5%), and internal trunk (20.5%).
  • Histologically, lesions show a varying combination of lipogenic and nonlipogenic areas characterized by malignant fibrous histiocytoma-like, round cell liposarcoma-like, and/or epithelioid/carcinoma-like features.
  • Tumor necrosis was observed in 51 (81%) cases, vascular invasion in three, and mitotic counts ranged from 3 to 124 per 10 high power fields (median 25).
  • Nonlipogenic areas showed focal reactivity for smooth muscle actin (24 of 49; 49%), desmin (9 of 48; 19%), CD34 (18 of 45; 40%), S-100 protein (5 of 49, 10%), CD68 (6 of 46, 13%), and epithelial membrane antigen (13 of 49, 26.5%).
  • Treatment procedures in 51 patients consisted of simple tumorectomy (16) and wide excision (33).
  • Five and 31 patients received neoadjuvant and adjuvant chemotherapy and/or radiation therapy, respectively.
  • Patient age > or =60 years, truncal tumor location, deep situation, tumor size >5 cm, vascular invasion, and incomplete tumor excision were significant adverse prognostic factors.
  • Tumor grade and histology did not affect patient outcome.
  • In conclusion, pleomorphic liposarcoma is a rare, often deep-seated and limb-based aggressive and metastasizing neoplasm of late adulthood.
  • It shows a wide range of morphologic appearances, but tumor grade and histology have no effect on patient outcome.
  • [MeSH-major] Liposarcoma / pathology. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Disease-Free Survival. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Proteins / analysis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11979090.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


22. Malpica A, Moran CA: Primitive neuroectodermal tumor of the cervix: a clinicopathologic and immunohistochemical study of two cases. Ann Diagn Pathol; 2002 Oct;6(5):281-7
International Agency for Research on Cancer - Screening Group. diagnostics - Histopathology and cytopathology of the uterine cervix - digital atlas .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primitive neuroectodermal tumor of the cervix: a clinicopathologic and immunohistochemical study of two cases.
  • Grossly, in both cases, the uterine cervix showed an ill-defined tumor involving the ectocervix and endocervix, measuring 3.0 and 4.0 cm in greatest dimension, respectively, and showing areas of necrosis and hemorrhage.
  • Histologic sections showed the presence of a malignant neoplasm arranged in cords and with a vague nesting pattern.
  • In one patient, the tumor had metastasized to lymph nodes.
  • Immunohistochemical studies revealed the neoplastic cells to be positive for antibodies for CD99 and focally for synaptophysin, while keratin, chromogranin, smooth muscle actin, desmin, and neurofilament protein were negative.
  • Both patients received adjuvant chemotherapy and remain alive 5 and 18 months after initial diagnosis, respectively.

  • MedlinePlus Health Information. consumer health - Cervical Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002, Elsevier Science (USA)
  • (PMID = 12376920.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Tanaka T, Toujima S, Utsunomiya T, Yukawa K, Umesaki N: Experimental characterization of recurrent ovarian immature teratoma cells after optimal surgery. Oncol Rep; 2008 Jul;20(1):13-23
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Minimal optimal surgery without chemotherapy is often performed for patients with ovarian immature teratoma, which frequently occurs in young women who hope for future pregnancies.
  • If tumors recur after the operation, anticancer drug chemotherapy is often administered, although few studies have highlighted differences between the recurrent and the primary tumor cells.
  • Therefore, we have established experimental animal models of recurrent ovarian immature teratoma cells after optimal surgery and characterized the anticancer drug sensitivity and antigenicity of the recurrent tumors.
  • Surgically-excised tumor cells of a grade II ovarian immature teratoma were cultured in vitro and transplanted into nude mice to establish stable cell lines.
  • Differential drug sensitivity and antigenicity of the tumor cells were compared between the primary and the nude mouse tumors.
  • Nude mouse tumor cells showed a normal 46XX karyotype.
  • Cultured primary cells showed a remarkably high sensitivity to paclitaxel, docetaxel, adriamycin and pirarubicin, compared to peritoneal cancer cells obtained from a patient with ovarian adenocarcinomatous peritonitis.
  • The drug sensitivity of teratoma cells to 5-fluorouracil, bleomycin or peplomycin was also significantly higher.
  • However, there was no significant difference in sensitivity to platinum drugs between the primary teratoma and the peritoneal adenocarcinoma cells.
  • As for nude mouse tumor cells, sensitivity to 12 anticancer drugs was significantly lower than that of the primary tumor cells, while there was little difference in sensitivity to carboplatin or peplomycin between the primary and nude mouse tumor cells.
  • Flow cytometry showed that the expression of smooth muscle actin (SMA) significantly decreased in nude mouse tumor cells when compared to cultured primary cells.
  • In conclusion, ovarian immature teratomas with normal karyotypes have a malignant potential to recur after minimal surgery.
  • During nude mouse transplantation, SMA-overexpressing cells appeared to be selectively excluded and nude mouse tumor cells were less sensitive to the majority of anticancer drugs than the primary tumor cells.
  • These results indicate that after optimal surgery for ovarian immature teratoma, recurrent cells can be more resistant to anticancer drugs than the primary tumors.
  • Therefore, it is likely that adjuvant chemotherapy lowers the risk of ovarian immature teratomas recurring after optimal surgery.
  • However, paclitaxel/carboplatin or docetaxel/carboplatin, which are the most effective chemotherapy treatments for epithelial ovarian cancer patients, are considered to be an alternative regimen, especially in the prevention of reproductive toxicity.
  • [MeSH-major] Neoplasm Recurrence, Local / pathology. Ovarian Neoplasms / pathology. Teratoma / pathology
  • [MeSH-minor] Adolescent. Animals. Cell Line, Tumor. Drug Screening Assays, Antitumor. Female. Flow Cytometry. Humans. Karyotyping. Mice

  • Genetic Alliance. consumer health - Teratoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18575713.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  •  go-up   go-down


24. Mankin HJ, Casas-Ganem J, Kim JI, Gebhardt MC, Hornicek FJ, Zeegen EN: Leiomyosarcoma of somatic soft tissues. Clin Orthop Relat Res; 2004 Apr;(421):225-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leiomyosarcoma of somatic soft tissues.
  • Leiomyosarcoma is a rare, aggressively malignant connective tissue tumor of mature adults, which arises from smooth muscle.
  • It occurs most frequently in the uterus, bowel, vascular tissues, and less commonly in somatic soft tissue or bone.
  • The tumor when it arises in soft tissue has distinctive histologic features which somewhat resemble malignant fibrous histiocytoma (otherwise known as myxofibrosarcoma).
  • Factors that increase the death rate include size of the tumor, Musculoskeletal Tumor Society Stage of disease, and to a lesser extent particularly in the lower extremities, anatomic site.
  • Radiation and chemotherapy had little direct effect on the outcome but patients treated with surgery and adjunctive agents seemed to live longer than their cohorts treated with surgery alone.
  • The purpose of this study is a general review of the clinical and prognostic features of this cancer.
  • [MeSH-major] Leiomyosarcoma / mortality. Leiomyosarcoma / pathology. Soft Tissue Neoplasms / mortality. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15123952.001).
  • [ISSN] 0009-921X
  • [Journal-full-title] Clinical orthopaedics and related research
  • [ISO-abbreviation] Clin. Orthop. Relat. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


25. Williams SB, Ellis GL, Warnock GR: Sialoblastoma: a clinicopathologic and immunohistochemical study of 7 cases. Ann Diagn Pathol; 2006 Dec;10(6):320-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sialoblastoma is a rare congenital or perinatal salivary tumor that varies in histologic features and biologic potential.
  • These tumors occurred in 4 males and 3 females with ages ranging from prenatal to 6 months at the time of discovery.
  • (1) a favorable pattern had semiencapsulation of cytologically benign basaloid tumor cells with intervening stroma; and (2) an unfavorable histology of anaplastic basaloid tumor cells, minimal stroma, and broad pushing to infiltrative periphery.
  • Tumor cells in 3 cases were immunohistochemically reactive for keratin, S-100, smooth muscle actin, and calponin to varying degrees.
  • Ki67 was expressed at 3% in a favorable tumor and 40% and 80% in the 2 unfavorable lesions.
  • Treatment involved surgical excision.
  • One patient received adjuvant chemotherapy.
  • Two sialoblastomas resulted in recurrences within a year and another developed a recurrence after 4 years.
  • One sialoblastoma developed lung metastasis within 1 month of the original biopsy.
  • [MeSH-major] Mixed Tumor, Malignant / secondary. Neoplasms, Glandular and Epithelial / secondary. Parotid Neoplasms / pathology. Submandibular Gland Neoplasms / pathology
  • [MeSH-minor] Biomarkers, Tumor / analysis. Female. Humans. Immunoenzyme Techniques. Infant. Infant, Newborn. Ki-67 Antigen / analysis. Male. Neoplasm Recurrence, Local. Treatment Outcome. alpha-Fetoproteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126248.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / alpha-Fetoproteins
  •  go-up   go-down


26. Wei S, Carroll W, Lazenby A, Bell W, Lopez R, Said-Al-Naief N: Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome. Ann Diagn Pathol; 2008 Dec;12(6):415-25
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sinonasal teratocarcinosarcoma: report of a case with review of literature and treatment outcome.
  • Sinonasal teratocarcinosarcoma is a highly malignant, polymorphous neoplasm that combines features of carcinosarcoma and teratoma.
  • Computerized tomography scans and magnetic resonance imaging revealed a large mass filling the left nasal cavity and extending to the cribriform plate with involvement of the ethmoid sinuses, lamina papyracea, and orbit.
  • The patient underwent a complex procedure for a T3N0 tumor.
  • The mesenchymal components consist of fibrous stroma and myxomatous areas, labeled with calponin and smooth muscle actin.
  • Immature neuroepithelium and olfactory neuroblastomalike tissue are highlighted with neuroendocrine markers.
  • Postoperatively, the patient had a rapid local recurrence of the tumor and underwent reexcision, and was treated with radiotherapy and chemotherapy.
  • Twelve months after his primary resection, computerized tomography scans revealed an intrathoracic tumor with dominant mass in the left hilum and metastases to the mediastinum, left pleural space, and both lungs.
  • Among 54 cases of reported sinonasal teratocarcinosarcoma, 67% of patients with initial single surgical resection and 80% of patients primarily treated with radiotherapy had recurrence, or metastatsis, or unresponsiveness to treatment.
  • Almost half of the patients died of tumor within 3 years of diagnosis, despite aggressive therapy.
  • Seventy percent of the patients who survived more than 1 year had the initial therapeutic regiments of combined surgery and adjuvant therapies, suggesting that aggressive therapeutic approaches may improve the treatment outcome.
  • [MeSH-major] Carcinosarcoma / diagnosis. Carcinosarcoma / therapy. Nose Neoplasms / diagnosis. Nose Neoplasms / therapy. Teratoma / diagnosis. Teratoma / therapy
  • [MeSH-minor] Adult. Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Paranasal Sinuses / pathology. Paranasal Sinuses / surgery. Prognosis. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18995206.001).
  • [ISSN] 1532-8198
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


27. De Flora S, Izzotti A, D'Agostini F, Balansky RM, Noonan D, Albini A: Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutat Res; 2001 Sep 1;480-481:9-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple points of intervention in the prevention of cancer and other mutation-related diseases.
  • Multiple points of intervention are the target for dietary and pharmacological interventions aimed at preventing cancer and other diseases in which mutations in somatic cells play a pathogenetic role.
  • For instance, our studies showed that DNA adducts can be consistently detected in arterial smooth muscle cells from human atherosclerotic lesions.
  • Cancer chemoprevention has a dual goal, i.e. prevention of occurrence of the disease (primary prevention) and early detection and reversion of tumors at a premalignant stage (secondary prevention).
  • At a later stage, attempts can be made to prevent local recurrences as well as invasion and metastasis of malignant cells (tertiary prevention).
  • We propose here a detailed, updated classification of the points of intervention exploitable in the prevention of mutation and cancer.
  • The general outline includes a variety of extracellular and cellular mechanisms modulating the genotoxic response and tumor initiation as well as tumor promotion, progression, angiogenesis, invasion, and metastasis.
  • This classification is not intended to provide a rigid scheme, since several intervention points are reiterated several times over different phases of the process.
  • [MeSH-minor] Animals. Antioxidants / pharmacology. Biomarkers, Tumor. Diet. Disease Progression. Drug Therapy, Combination. Humans. Neoplasm Invasiveness / prevention & control. Neoplasm Metastasis / prevention & control. Retinoids / pharmacology. Risk Factors

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11506795.001).
  • [ISSN] 0027-5107
  • [Journal-full-title] Mutation research
  • [ISO-abbreviation] Mutat. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers, Tumor; 0 / Retinoids
  • [Number-of-references] 59
  •  go-up   go-down


28. de la Roza G, Naqvi A, Clark K: Gastrointestinal stromal tumors presenting as a prostatic mass. Can J Urol; 2009 Feb;16(1):4502-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • These tumors are characterized by somatic mutations of c-KIT (CD117), a proto-oncogene that encodes a receptor tyrosine kinase normally expressed in the interstitial cell of Cajal that control the GI smooth muscle peristalsis, and an exquisite sensitivity to the action of the tyrokinase inhibitor imatinib mesylate (STI571; Gleevec).
  • We report two cases of gastrointestinal stromal tumor identified on prostatic biopsies, where a primary prostatic sarcoma was considered in the differential diagnosis.
  • In one of the cases, there was extensive local disease involving prostate, rectum, and pelvic wall, as well as metastatic disease that quickly lead to the patient's death despite aggressive treatment with imatinib mesylate and conventional chemotherapy.
  • In the other case, the tumor was mostly confined to the rectum but also focally extended into the prostate capsule.
  • In both cases, tissue samples from prostate and the rectum showed a malignant spindle cell neoplasm, which was positive for CD117 (c-kit).

  • Genetic Alliance. consumer health - Gastrointestinal Stromal Tumors.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222892.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


29. Marti A, Jichlinski P, Lange N, Ballini JP, Guillou L, Leisinger HJ, Kucera P: Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer. J Urol; 2003 Aug;170(2 Pt 1):428-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of aminolevulinic acid and hexylester aminolevulinate induced protoporphyrin IX distribution in human bladder cancer.
  • PURPOSE: Successful photodynamic therapy of epithelial cancer requires a specific photosensitization of malignant tissue.
  • RESULTS: Topical bladder instillation with 180 mmol (3%) ALA administered for 6 hours or 8 mmol (0.2%) HAL administered for 4 hours gave similar results regarding intensity and tissue distribution of PpIX fluorescence, whereas 8 mmol HAL administered for 2 hours followed by 2 hours of resting time (2+2 hours concept) induced a PpIX fluorescence twice as high.
  • The fluorescence remained limited to cancer cells.
  • Only a trace of PpIX fluorescence was observed in suburothelial connective tissue, that is chorion, but none in the bladder smooth muscle regardless of experiment conditions.
  • CONCLUSIONS: HAL is an excellent precursor for PpIX synthesis in bladder cancer.
  • With the 2+2 hour topical administration condition it yielded the highest PpIX fluorescence intensity and fluorescence contrast between normal and malignant urothelial cells.
  • This approach allows us to optimize PpIX tissue distribution for photodynamic therapy in superficial bladder cancer.
  • [MeSH-major] Aminolevulinic Acid / administration & dosage. Aminolevulinic Acid / therapeutic use. Carcinoma, Transitional Cell / drug therapy. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy. Photosensitizing Agents / administration & dosage. Protoporphyrins / pharmacokinetics. Urinary Bladder Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Bladder cancer.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12853792.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Photosensitizing Agents; 0 / Protoporphyrins; 88755TAZ87 / Aminolevulinic Acid; C2K325S808 / protoporphyrin IX; G7H20TKI67 / 5-aminolevulinic acid hexyl ester
  •  go-up   go-down


30. Kratz KG, Santillan A, Gu M, Bristow RE: Radical surgical cytoreduction of progressive leiomyomatosis peritonealis disseminata: a case report. J Reprod Med; 2009 Jul;54(7):447-50

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Leiomyomatosis peritonealis disseminata (LPD) is an uncommon, benign smooth muscle condition of the peritoneal cavity that appears clinically as a metastatic malignant neoplasm.
  • This unique case involves curative radical surgery after disease progression during depo-medroxyprogesterone acetate therapy.
  • Despite initial surgery and hormonal therapy, she had progression of disease.
  • Tumor response to megestrol acetate in vitro was evaluated and noted to be heterogeneous; therefore it was not given as adjuvant therapy.
  • Five years after radical surgery, she was without evidence of disease, CONCLUSION: Radical secondary cytoreductive surgery can achieve a durable remission for LPD refractory to primary surgical castration and depomedroxyprogesterone acetate therapy.
  • [MeSH-minor] Adult. Disease Progression. Dose-Response Relationship, Drug. Female. Humans. Medroxyprogesterone Acetate / administration & dosage. Peritoneal Cavity / cytology. Peritoneal Cavity / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691262.001).
  • [ISSN] 0024-7758
  • [Journal-full-title] The Journal of reproductive medicine
  • [ISO-abbreviation] J Reprod Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] C2QI4IOI2G / Medroxyprogesterone Acetate
  •  go-up   go-down


31. Raschi E, Vasina V, Poluzzi E, De Ponti F: The hERG K+ channel: target and antitarget strategies in drug development. Pharmacol Res; 2008 Mar;57(3):181-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The hERG K+ channel: target and antitarget strategies in drug development.
  • The human ether-à-go-go related gene (hERG) K+ channel is of great interest for both basic researchers and clinicians because its blockade by drugs can lead to QT prolongation, which is a risk factor for torsades de pointes, a potentially life-threatening arrhythmia.
  • Thus, hERG K+ channels have become a primary antitarget (i.e. an unwanted target) in drug development because their blockade causes potentially serious side effects.
  • On the other hand, the recent identification and functional characterization of hERG K+ channels not only in the heart, but also in several other tissues (e.g. neurons, smooth muscle and cancer cells) may have far reaching implications for drug development for a possible exploitation of hERG as a target, especially in oncology and cardiology.
  • [MeSH-major] Ether-A-Go-Go Potassium Channels / drug effects. Potassium Channel Blockers / pharmacology
  • [MeSH-minor] Animals. Arrhythmias, Cardiac / drug therapy. Arrhythmias, Cardiac / physiopathology. Humans. Long QT Syndrome / drug therapy. Neoplasms / drug therapy. Torsades de Pointes / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18329284.001).
  • [ISSN] 1043-6618
  • [Journal-full-title] Pharmacological research
  • [ISO-abbreviation] Pharmacol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Ether-A-Go-Go Potassium Channels; 0 / Potassium Channel Blockers
  • [Number-of-references] 160
  •  go-up   go-down


32. Lam MM, Corless CL, Goldblum JR, Heinrich MC, Downs-Kelly E, Rubin BP: Extragastrointestinal stromal tumors presenting as vulvovaginal/rectovaginal septal masses: a diagnostic pitfall. Int J Gynecol Pathol; 2006 Jul;25(3):288-92
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Gastrointestinal stromal tumor (GIST) are the most common mesenchymal tumors of the gastrointestinal (GI) tract.
  • Because of their malignant potential and recent advances in the management of GISTs with imatinib mesylate (Gleevec, Glivec), it is imperative that these tumors are correctly diagnosed.
  • All 3 lesions had a spindle cell morphology that mimicked a smooth muscle tumor.
  • Immunohistochemistry revealed that all 3 cases were strongly positive for KIT (CD117) and CD34 and negative for smooth muscle actin, desmin, pan-cytokeratin, and estrogen receptor.
  • The first tumor recurred at 2 years and the second tumor recurred at 10 years; the third case is too recent for meaningful follow-up.
  • Misdiagnosis may lead to inappropriate therapy because conventional chemotherapy and radiotherapy are not effective in the treatment of GISTs, whereas imatinib mesylate (Gleevec, Glivec) has a proven role in managing these tumors.
  • [MeSH-minor] Adult. Antigens, CD34 / analysis. Antineoplastic Agents / therapeutic use. Benzamides. DNA, Neoplasm / genetics. Diagnosis, Differential. Female. Humans. Imatinib Mesylate. Immunohistochemistry. Leiomyoma / chemistry. Leiomyoma / diagnosis. Leiomyoma / genetics. Leiomyoma / pathology. Leiomyosarcoma / chemistry. Leiomyosarcoma / diagnosis. Leiomyosarcoma / genetics. Leiomyosarcoma / pathology. Middle Aged. Mutation / genetics. Piperazines / therapeutic use. Proto-Oncogene Proteins c-kit / analysis. Proto-Oncogene Proteins c-kit / genetics. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • MedlinePlus Health Information. consumer health - Vulvar Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16810068.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzamides; 0 / DNA, Neoplasm; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


33. Prunotto M, Bosco M, Daniele L, Macri' L, Bonello L, Schirosi L, Rossi G, Filosso P, Mussa B, Sapino A: Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta. Lung Cancer; 2009 May;64(2):244-6
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imatinib inhibits in vitro proliferation of cells derived from a pleural solitary fibrous tumor expressing platelet-derived growth factor receptor-beta.
  • We examined the in vitro effects of imatinib (Novartis Pharma AG, Basel, Switzerland) as a possible inhibitor of PDGFR pathway on cells derived from a recurrence of a pleural malignant solitary fibrous tumor (SFT).
  • SFT-derived cells were treated with imatinib at different time points.
  • Western blotting for PDGFR-beta, phospho-PDGFR-beta or smooth muscle actin (SMA) was performed before and after 96 h of treatment with imatinib.
  • Western blotting showed that PDGFR-beta was highly expressed and phosphorylated in SFT-derived cells and imatinib treatment reduced PDGFR-beta phosphorylation and SMA expression.
  • With the limit of experimental findings, our results support a possible future application of imatinib as a candidate molecule in the target therapy of malignant SFTs over-expressing wild-type PDGFR.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Cell Proliferation / drug effects. Piperazines / pharmacology. Pyrimidines / pharmacology. Receptor, Platelet-Derived Growth Factor beta / drug effects. Solitary Fibrous Tumor, Pleural / metabolism
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides. Blotting, Western. Cells, Cultured. Cisplatin / administration & dosage. Female. Fluorescent Antibody Technique. Fluorouracil / administration & dosage. Humans. Imatinib Mesylate. In Vitro Techniques. Neoplasm Recurrence, Local / metabolism. Neoplasm Recurrence, Local / pathology. Pneumonectomy. Radiotherapy. Receptor, Platelet-Derived Growth Factor alpha / biosynthesis

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. IMATINIB MESYLATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19041155.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor alpha; EC 2.7.10.1 / Receptor, Platelet-Derived Growth Factor beta; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  •  go-up   go-down






Advertisement